​

Nektar Therapeutics (NKTR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NKTR Stock Forecast

Nektar Therapeutics (NKTR) stock forecast, based on 32 Wall Street analysts, predicts a 12-month average price target of $119.00, with a high of $135.00 and a low of $105.00. This represents a 231.38% increase from the last price of $35.91.

- $30 $60 $90 $120 $150 High: $135 Avg: $119 Low: $105 Last Closed Price: $35.91

NKTR Stock Rating

Nektar Therapeutics stock's rating consensus is Buy, based on 32 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (68.75%), 5 Hold (15.62%), 5 Sell (15.62%), and 0 Strong Sell (0.00%).

Buy
Total 32 0 5 5 22 Strong Sell Sell Hold Buy Strong Buy

NKTR Price Target Upside V Benchmarks

TypeNameUpside
StockNektar Therapeutics231.38%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts145
Avg Price Target$105.00$119.00$115.00
Last Closing Price$35.91$35.91$35.91
Upside/Downside192.40%231.38%220.25%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26161--8
Dec, 25161--8
Nov, 25241-18
Oct, 25241-18
Sep, 25241-18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 26, 2026Yasmeen RahimiPiper Sandler$105.00$36.35188.86%192.40%
Dec 16, 2025H.C. Wainwright$135.00$51.17163.83%275.94%
Dec 16, 2025Jay OlsonOppenheimer$115.00$50.43128.04%220.25%
Nov 24, 2025Roger SongJefferies$121.00$54.28122.92%236.95%
Sep 18, 2025Roger SongJefferies$99.00$58.7468.54%175.69%
Apr 18, 2022Mara GoldsteinMizuho Securities$6.00$4.7426.58%-83.29%
Mar 01, 2022Jessica FyeJ.P. Morgan$17.00$10.9854.83%-52.66%
Nov 08, 2021Aydin HuseynovLadenburg Thalmann & Co.$20.00$14.6536.52%-44.31%
May 18, 2021Chris ShibutaniGoldman Sachs$24.00$18.1332.38%-33.17%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 26, 2026Piper SandlerOverweightOverweighthold
Dec 17, 2025JefferiesBuyBuyhold
Dec 16, 2025H.C. WainwrightBuyBuyhold
Dec 16, 2025OppenheimerOutperformOutperformhold
Nov 26, 2025CitigroupBuyinitialise
Nov 24, 2025JefferiesBuyBuyhold
Oct 15, 2025B. RileyBuyBuyhold
Sep 18, 2025JefferiesBuyBuyhold
Sep 04, 2025UBSOverweightOverweighthold
Jun 24, 2025JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.86$-1.97$-1.45$-0.58----
Avg Forecast$-2.90$-2.13$-1.44$-0.72$-0.77$-0.70$-0.75$-0.76
High Forecast$-1.15$-0.99$-1.41$-0.46$-0.61$-0.38$-0.29$-0.21
Low Forecast$-3.89$-3.72$-1.47$-0.83$-0.93$-0.89$-1.05$-1.41
Surprise %-1.38%-7.51%0.69%-19.44%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$101.91M$92.06M$90.12M$98.43M----
Avg Forecast$111.04M$91.46M$84.89M$104.74M$81.59M$80.39M$89.61M$139.94M
High Forecast$140.30M$144.24M$91.13M$155.05M$139.21M$81.71M$89.81M$233.57M
Low Forecast$59.55M$53.80M$72.68M$90.37M$37.45M$79.08M$89.41M$62.83M
Surprise %-8.23%0.65%6.17%-6.03%----

Net Income Forecast

$-750M $-600M $-450M $-300M $-150M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-523.84M$-368.20M$-276.06M$-118.96M----
Avg Forecast$-555.71M$-614.62M$-276.06M$-121.91M$-172.26M$-121.25M$-127.20M$-143.64M
High Forecast$-444.57M$-491.70M$-220.84M$-86.95M$-116.82M$-72.93M$-54.65M$-40.74M
Low Forecast$-666.85M$-737.55M$-331.27M$-156.88M$-176.13M$-169.57M$-199.75M$-268.58M
Surprise %-5.74%-40.09%--2.42%----

NKTR Forecast FAQ

Is Nektar Therapeutics stock a buy?

Nektar Therapeutics stock has a consensus rating of Buy, based on 32 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 5 Hold, 5 Sell, and 0 Strong Sell, reflecting a consensus that Nektar Therapeutics is a favorable investment for most analysts.

What is Nektar Therapeutics's price target?

Nektar Therapeutics's price target, set by 32 Wall Street analysts, averages $119 over the next 12 months. The price target range spans from $105 at the low end to $135 at the high end, suggesting a potential 231.38% change from the previous closing price of $35.91.

How does Nektar Therapeutics stock forecast compare to its benchmarks?

Nektar Therapeutics's stock forecast shows a 231.38% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Nektar Therapeutics over the past three months?

  • January 2026: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 25.00% Strong Buy, 50.00% Buy, 12.50% Hold, 0% Sell, 12.50% Strong Sell.

What is Nektar Therapeutics’s EPS forecast?

Nektar Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.77, marking a 32.76% increase from the reported $-0.58 in 2024. Estimates for the following years are $-0.7 in 2026, $-0.75 in 2027, and $-0.76 in 2028.

What is Nektar Therapeutics’s revenue forecast?

Nektar Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $81.59M, reflecting a -17.11% decrease from the reported $98.43M in 2024. The forecast for 2026 is $80.39M, followed by $89.61M for 2027, and $139.94M for 2028.

What is Nektar Therapeutics’s net income forecast?

Nektar Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-172M, representing an 44.81% increase from the reported $-119M in 2024. Projections indicate $-121M in 2026, $-127M in 2027, and $-144M in 2028.